{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:31:24Z","timestamp":1707525084235},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,4]]},"DOI":"10.7759\/cureus.37113","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T17:27:20Z","timestamp":1680629240000},"source":"Crossref","is-referenced-by-count":0,"title":["Sickle Cell Disease (SCD) Leading to Pulmonary Arterial Hypertension (PAH) and Cholelithiasis (CL)"],"prefix":"10.7759","author":[{"given":"Saran","family":"Chacko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulhas","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babaji","family":"Ghewade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Wagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshan","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur B","family":"Wanjari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/aam.aam_81_20","article-title":"Cholelithiasis in children and adolescents with sickle cell disease: experience in a resource-limited setting","volume":"21","author":"Adeniyi OF","year":"2022","unstructured":"Adeniyi OF, Akinsete AM, Odeghe EA, Olowoyeye OA, Okeke OF, Seyi-Olajide JO, Akinsulie A. Cholelithiasis in children and adolescents with sickle cell disease: experience in a resource-limited setting. Ann Afr Med. 2022, 21:58-64. 10.4103\/aam.aam_81_20","journal-title":"Ann Afr Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7489.432","article-title":"Mortality from sickle cell disease in Africa","volume":"330","author":"Serjeant GR","year":"2005","unstructured":"Serjeant GR. Mortality from sickle cell disease in Africa. BMJ. 2005, 330:432-3. 10.1136\/bmj.330.7489.432","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24993","article-title":"Demographic and risk factor profile in patients of gallstone disease in central India","volume":"14","author":"Patel AM","year":"2022","unstructured":"Patel AM, Yeola M, Mahakalkar C. Demographic and risk factor profile in patients of gallstone disease in central India. Cureus. 2022, 14:e24993. 10.7759\/cureus.24993","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/ejh.ejh_34_18","article-title":"Asymptomatic gallstones in patients with sickle cell disease: to wait or to operate?","volume":"44","author":"El-Menoufy M","year":"2019","unstructured":"El-Menoufy M, El-Barbary HM, Raslan SM. Asymptomatic gallstones in patients with sickle cell disease: to wait or to operate? . Egyptian J Haematol. 2019, 44:28-33. 10.4103\/ejh.ejh_34_18","journal-title":"Egyptian J Haematol"},{"key":"ref5","article-title":"The study on clinical profile of patients with gallstones","volume":"3","author":"Singh AK","year":"2017","unstructured":"Singh AK, Singh SP. The study on clinical profile of patients with gallstones. Int J Med Health Res. 2017, 3:99-102.","journal-title":"Int J Med Health Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4236\/ojepi.2020.104028","article-title":"The prevalence and severity of gallstones in sickle cell disease in Kuwait","volume":"10","author":"Al-Jafar HA","year":"2020","unstructured":"Al-Jafar HA, Hayati HA, AlKhawari H, AlThallab FS, Al-Ali M. The prevalence and severity of gallstones in sickle cell disease in Kuwait. Open J Epidemiol. 2020, 10:346-54. 10.4236\/ojepi.2020.104028","journal-title":"Open J Epidemiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-618561","article-title":"Pathophysiology and treatment of pulmonary hypertension in sickle cell disease","volume":"127","author":"Gordeuk VR","year":"2016","unstructured":"Gordeuk VR, Castro OL, Machado RF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood. 2016, 127:820-8. 10.1182\/blood-2015-08-618561","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201401-0065ST","article-title":"An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease","volume":"189","author":"Klings ES","year":"2014","unstructured":"Klings ES, Machado RF, Barst RJ, et al.. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014, 189:727-40. 10.1164\/rccm.201401-0065ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000766","article-title":"Sildenafil for Pulmonary Arterial Hypertension","volume":"26","author":"Bhogal S","year":"2019","unstructured":"Bhogal S, Khraisha O, Al Madani M, Treece J, Baumrucker SJ, Paul TK. Sildenafil for Pulmonary Arterial Hypertension. Am J Ther. 2019, 26:e520-6. 10.1097\/MJT.0000000000000766","journal-title":"Am J Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201111-2082CI","article-title":"Pulmonary complications of sickle cell disease","volume":"185","author":"Miller AC","year":"2012","unstructured":"Miller AC, Gladwin MT. Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med. 2012, 185:1154-65. 10.1164\/rccm.201111-2082CI","journal-title":"Am J Respir Crit Care Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000519101","article-title":"Sickle cell disease-induced pulmonary hypertension: a review of pathophysiology, management, and current literature","volume":"9","author":"Sheikh AB","year":"2021","unstructured":"Sheikh AB, Nasrullah A, Lopez ED, et al.. Sickle cell disease-induced pulmonary hypertension: a review of pathophysiology, management, and current literature. Pulse (Basel). 2021, 9:57-63. 10.1159\/000519101","journal-title":"Pulse (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-013-0261-4","article-title":"Hydroxyurea in sickle cell disease: drug review","volume":"30","author":"Agrawal RK","year":"2014","unstructured":"Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus. 2014, 30:91-6. 10.1007\/s12288-013-0261-4","journal-title":"Indian J Hematol Blood Transfus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/132325-sickle-cell-disease-scd-leading-to-pulmonary-arterial-hypertension-pah-and-cholelithiasis-cl","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:17Z","timestamp":1707508637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/132325-sickle-cell-disease-scd-leading-to-pulmonary-arterial-hypertension-pah-and-cholelithiasis-cl"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.37113","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,4]]}}}